# Chloride channel accessory 4 suppresses stem cell-like properties of colorectal cancer and enhances anti-PD-1 immunotherapy

**Authors:** Fang Wei, Qi Zou, Qihui Sun, Tingting Jiang, Tian Cai, Xiaojia Li, Keping Xie

PMC · DOI: 10.1016/j.gendis.2025.101859 · Genes & Diseases · 2025-09-20

## TL;DR

This study shows that CLCA4 reduces stem cell-like properties in colorectal cancer and improves the effectiveness of anti-PD-1 immunotherapy.

## Contribution

The novel contribution is the discovery that CLCA4 suppresses cancer stem cell properties by interacting with vimentin and inhibiting the FAK pathway.

## Key findings

- CLCA4 inhibits stemness genes and reduces tumorsphere formation in colorectal cancer stem cells.
- CLCA4 interacts with vimentin to inactivate the FAK pathway and suppress cancer stem cell expansion.
- Increased CLCA4 expression enhances anti-PD-1 therapy by promoting CD8+ T cell infiltration.

## Abstract

Reduced chloride channel accessory 4 (CLCA4) levels are linked to cancer development, while its role and mechanism in cancer stem cells (CSCs) remain unclear. In this study, we discovered that decreased CLCA4 expression was evident in CD133+CD44+ colorectal CSCs and chemoresistant colorectal cancer (CRC) cells. Increased expression of CLCA4 inhibited the expression of stemness genes, reduced tumorsphere formation, suppressed the self-renewal, migratory, and invasive capabilities of colorectal CSCs in vitro, and suppressed the tumorigenicity of colorectal CSCs in vivo. Mechanistically, CLCA4 interacted with vimentin, leading to FAK pathway inactivation and subsequent suppression of CSC expansion, while vimentin up-regulation attenuated the effects of CLCA4 down-regulation and established its role in CLCA4-mediated colorectal CSC self-renewal. Decreased CLCA4 expression was positively correlated with colorectal CSC markers and vimentin in clinical specimens. Increased CLCA4 expression promoted the infiltration of cytotoxic CD8+ T cells and enhanced the anti-PD-1 therapeutic efficacy. Our findings suggest that CLCA4 could impede colorectal CSC self-renewal by interacting with vimentin to suppress the FAK signaling pathway, potentially reducing tumor cell stemness and evading immune surveillance. The new findings on cellular and molecular mechanisms underpinning CRC development and progression could offer new perspectives for potential intervention and treatment of CRC.

## Linked entities

- **Genes:** CLCA4 (chloride channel accessory 4) [NCBI Gene 22802], PRELID1 (PRELI domain containing 1) [NCBI Gene 737446], PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747], PROM1 (prominin 1) [NCBI Gene 8842], CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960]
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** PROM1 (prominin 1) [NCBI Gene 8842] {aka AC133, CD133, CORD12, MCDR2, MSTP061, PROML1}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, VIM (vimentin) [NCBI Gene 7431], CLCA4 (chloride channel accessory 4) [NCBI Gene 22802] {aka CaCC, CaCC2}
- **Diseases:** cancer (MESH:D009369), CRC (MESH:D015179)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12886529/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12886529/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12886529/full.md

---
Source: https://tomesphere.com/paper/PMC12886529